Introduction {#Sec1}
============

Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary bypass for patients with pulmonary or circulatory failure unresponsive to conventional treatment. Most patients are heavily sedated to prevent accidental decannulation or impeded ECMO flow due to movement or suboptimal cannula position. However, prolonged and high cumulative doses of opioids and benzodiazepines have been associated with tolerance, physical dependency, and consequently withdrawal syndrome in neonates and children \[[@CR1]--[@CR5]\]. Sedation guidelines for pediatric ICU patients have been developed but are in part hampered by the lack of high-quality evidence, and exclude neonates and ECMO patients \[[@CR6], [@CR7]\]. Strategies to decrease cumulative doses and duration of continuous infusions with the intent to reduce consequent adverse events include daily interruption or even complete withholding of continuous sedation \[[@CR8], [@CR9]\]. The latter strategies were both shown to significantly reduce total cumulative doses of sedative drugs without an increase in complications. More importantly, ventilator-free days, length of ICU stay, and occurrence of posttraumatic stress syndrome were also significantly reduced \[[@CR10]--[@CR12]\]. Two meeting reports on daily interruption in children presented a reduction of midazolam dose in the intervention group; both studies lacked power to show an effect on mechanical ventilation or ICU stay \[[@CR13], [@CR14]\]. To our knowledge, there are no such data on neonates or children on ECMO support.

The aim of our study is therefore to evaluate safety and feasibility of initial interruption of analgesia and sedatives in neonates following cannulation for ECMO.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

Prospective observational cohort study at a designated ECMO center.

The institutional medical ethics review board approved the study, and informed consent was obtained from the parents or legal representatives.

Patients {#Sec4}
--------

All neonates \<7 days old admitted for ECMO in 1 year were eligible for enrolment.

Criteria for ECMO treatment were: gestational age \>34 weeks, birth weight \>2.0 kg, mechanical ventilation \<7 days, alveolar arterial oxygen difference \>600 mmHg, and oxygenation index \>25 for more than 6 h.

All received standardized anesthesia during cannulation, consisting of fentanyl 5 mcg/kg bolus injection, morphine 50 mcg/kg/u, and midazolam 200 mcg/kg/u continuous infusion during cannulation. On ICU admission, severity of illness was assessed using the Score for Neonatal Acute Physiology Version II (SNAP II) and the Score for Neonatal Acute Physiology, Perinatal Extension, Version II (SNAPPE II).

Sedation and analgesia assessment {#Sec5}
---------------------------------

Pain and sedation were routinely assessed by the attending nurse using validated pain (visual analog scale, VAS) and sedation (COMFORT-B) scores \[[@CR15], [@CR16]\]. Morphine and midazolam infusions were discontinued 30--60 min after cannulation and resumed on the guidance of regularly determined CS and VAS scores.

When COMFORT-B score was 17 or higher, continuous midazolam 100 mcg/kg/h was started after a loading dose of 200 mcg/kg. Morphine 10 mcg/kg/u was started after a loading dose of 100 mcg/kg when VAS score was 4 or higher, or when sedation was ineffective with midazolam (\>300 mcg/kg/u), or at the discretion of the attending medical team. Fentanyl was used for procedural analgesia or as rescue medication.

### Outcome parameters {#Sec6}

Primary:duration of sedation interruptionSecondary:need for rescue medication and number of complications (extubations, decannulation, impairment of ECMO flow by 50%)

Statistical analysis {#Sec7}
--------------------

All values are presented as median (IQR) unless otherwise indicated. Groups were compared using Mann--Whitney test. For correlation analyses the Spearman signed-rank test was used. A *p* value \<0.05 was considered significant. All statistical analyses were performed using Graphpad Prism v4 (Graphpad Software Inc., La Jolla CA, USA).

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

Twenty-seven patients received ECMO support during the study period. Twenty-one met the inclusion criterion, but one of them died within 24 h after cannulation. So, the analysis included 20 patients. Median postnatal age (range) was 0.79 (0.17--5.8) days (Table [1](#Tab1){ref-type="table"}). All patients received midazolam median (IQR) 110 mcg/kg/u (100--200 mcg/kg/u) and morphine 10.9 mcg/kg/u (10--20 mcg/kg/u) before cannulation. Five received phenobarbital for suspected convulsions prior to cannulation for ECMO. Twelve patients received vecuronium bromide prior to ECMO. All patients received inotropic support and antibiotics.Table 1Clinical characteristicsPatients (*n*)20Female/male (*n*)10/10Mortality (%)25CDH7MAS10Pneumonia1Sepsis1Pulmonary valve atresia1 Median (IQR)(Range)SNAP II16 (16--23)(26--35)SNAPPE II33 (16--34)(16--54)Oxygenation index prior to ECMO38(21--54)AaDO~2~ prior to ECMO (mmHg)599(522--624)Age (days)0.79 (0.29--3.4)(0.17--6.8)Length of ECMO (h)123 (88--218)(53--462)Gestational age (weeks)40 1/7 (38 1/7--41 4/7)(35/5/7--42 3/7)Birth weight (kg)3.1 (2.8--3.6)(2.3--4.0)Morphine dose pre-ECMO (mcg/kg/u)10.9 (10--20)(8.8--33)Midazolam dose pre-ECMO (mcg/kg/u)110 (100--200)(50--220)Data given are number of patients or median values (IQR) (range)*CDH* congenital diaphragmatic hernia, *MAS* meconium aspiration syndrome, *AaDO*~*2*~ arterial alveolar oxygen difference

Sedation interruption {#Sec10}
---------------------

Midazolam was discontinued in all 20 patients; morphine in 18. Median interruption time for both drugs combined was 10.3 h (IQR 5.0--24.1 h). Median interruption time for midazolam was 16.5 h (IQR 6.6--29.6); median interruption time for morphine was 11.2 h (IQR 6.7--39.4 h) (Fig. [1](#Fig1){ref-type="fig"}). Interruption times were shorter for patients with higher cumulative doses of midazolam or morphine (*r* = −0.54, *p* = 0.013 and *r* = −0.58, *p* = 0.008, respectively).Fig. 1Individual interruption times of midazolam, morphine, and of both sedatives. Each *dot* represents one patient

Interruption times for patients with meconium aspiration syndrome were shorter than for patients with other diagnoses; the difference did not reach statistical significance \[6.8 h (3.2--15.2 h) versus 16.0 h (8.7--35.1 h), *p* = 0.07\].

Duration of interruption did not differ between patients with and without concomitant phenobarbital use, male and female patients, or survivors and nonsurvivors. There was no significant correlation between SNAP II or SNAPPE II score and interruption time.

Safety {#Sec11}
------

No accidental decannulations or extubations during sedation interruption were observed, neither agitation resulting in impairment of ECMO flow nor accidental bleeding.

Rescue medication {#Sec12}
-----------------

Three patients (15%) received fentanyl during the interruption period, one for perceived discomfort and two for procedural analgesia.

Level of sedation {#Sec13}
-----------------

Both CS and VAS scores were low during sedation interruption (Table [2](#Tab2){ref-type="table"}). In seven patients (35%) midazolam or morphine was restarted on the guidance of COMFORT-B score \>17. In the other 13 patients either no CS was recorded at the moment of restart of medication (*n* = 7) or midazolam or morphine was started despite COMFORT-B or VAS score below the cutoff point (*n* = 6). Reasons for start of medication were: perceived discomfort manifesting as unexplained cardiovascular or respiratory instability, or suspected discomfort in anticipation of a medical procedure.Table 2Interruption duration, plasma levels, CS, and VAS at restart of medicationMedianIQRRangeInterruption duration (h)10:255:00--24:100:00--57:30Median CS during cessation of medication8.58--97--15VAS10--20--5CS at restart of medication (*n* = 13)1711--1810--21

Discussion {#Sec14}
==========

To our knowledge this is the first study that shows that prolonged interruption of sedatives and analgesics is feasible in neonates on ECMO. Interruption of morphine or midazolam did not cause any major complications. On average, patients remained adequately sedated for 10 h after cessation of medication. This is much longer than reported in adult patients not on ECMO \[[@CR8]\].

In the present study median COMFORT-B scores during the study period were low overall: 8.5 (IQR8-9), indicating oversedation \[[@CR17]\]. In combination with predominantly low COMFORT-B and VAS scores at time of restart of sedatives, this goes to show that, if anything, sedation was reintroduced early rather than late. In line with adult studies, interruption of medication seems more effective in preventing oversedation than does protocolized sedation alone.

Potentially altered disposition or effect of the drugs given, due to age, pre-existing disease, cannulation or ECMO treatment, could play a role in the longer interruption duration in our patients compared with adults. As all were younger than 7 days, effect of age on interruption duration could not be studied. We could not identify a relation between critical illness scores and interruption duration. Pharmacokinetic data of midazolam in these patients show increased volume of distribution and clearance on ECMO \[[@CR18]\]. This suggests that the observed interruption times are not related to increased plasma levels on ECMO.

We did find a shorter interruption duration in patients with high cumulative doses of morphine and midazolam prior to ECMO treatment, which could imply increased tolerance to both drugs.

As a limitation of the study, there was a high percentage of protocol violation. In 60% of cases morphine was started prior or simultaneously with midazolam; in 10% morphine was never discontinued. In all but one patient VAS scores were below 4, indicating no pain at time of morphine restart. Morphine was mostly used as a sedative, either as first choice or as an addition to midazolam even when midazolam dose was below 300 mcg/kg/u. The attending physician was allowed to deviate from protocol based on clinical assessment of the patient. In many neonatal ICUs morphine is the sedative of choice in ventilated (pre-)term infants, therefore attending physicians may opt for morphine more easily than for midazolam. Furthermore, procedures perceived as painful may have elicited the choice for morphine as a prophylactic analgesic. Due to these protocol violations it is impossible to discriminate between the sedative effects of midazolam and morphine in this study.

A second limitation lies in either missing or low COMFORT-B scores at restart of medication. In two patients medication was restarted prior to a procedure without scores being performed. In nine patients nurses indicated that the patient was uncomfortable or more awake than deemed necessary, despite low COMFORT-B scores. Ista et al. \[[@CR17]\] showed that interpretation of CS scores between 11 and 22 is difficult in children on the ICU and may necessitate an additional score.

Finally, doctors' and nurses' fear of accidental decannulation or ECMO system failures may precipitate earlier restart of sedatives. Our findings suggest that the actual interruption duration could have been longer if protocol compliance had been better.

Mulla et al. \[[@CR19]\] reported 100% adequate sedation with midazolam and morphine in a study cohort of 20 neonates on ECMO; unfortunately, dose adjustments were not reported. Our findings are in line with previous studies showing that, even if patients are oversedated and sedation protocols dictate to lower doses of sedative drug, these dose adjustments are not always made \[[@CR20]\].

Conclusions {#Sec15}
===========

Interruption of sedatives and analgesics is feasible and safe in neonates on ECMO without increased risk of complications. Interruption times are 2--3 times longer than reported in adult ICU patients. Future trials are needed to substantiate these findings and evaluate outcome benefits.
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